Editor’s Note: This week, we’re featuring a sector that Chief Income Strategist Marc Lichtenfeld calls “the most important in the market” – the biotech sector.
Marc is no stranger to biotech investing…
In fact, recently, he led his readers to a 2,381% partial options win on AbbVie (NYSE: ABBV).
Read on to learn what makes this sector so special.
– Mable Buchanan, Managing Editor
Many of you know Chief Income Strategist Marc Lichtenfeld as the “income guy” because of his work with The Oxford Income Letter…
But he’s as passionate about biotech investing as he is about dividends.
In fact, he’s been tracking the sector for several decades now and has spoken about biotech opportunities at events all over the world.
One of these events just ended this week: the 39th Annual J.P. Morgan Health Care Conference, which took place virtually from January 11 through January 14.
This year’s conference took on subjects like healthcare disparities, the rise of outpatient surgery centers and even the development of germ-killing robots.
In honor of this event, which hosts the best and brightest upcoming companies and is often rife with exciting announcements, we’ve decided to revisit one of Marc’s most popular State of the Market videos…
It’s important – no matter how exciting a biotech company’s technology may be or how compelling its story may be – to ensure that its business is healthy as well.
So in this short video, Marc outlines the five specific qualifications he looks for before recommending a biotech company.